Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  260.11
-5.73 (-2.16%)
AAPL  311.30
-5.53 (-1.75%)
AMD  469.45
+3.03 (0.65%)
BAC  61.86
-1.31 (-2.07%)
GOOG  338.20
-3.50 (-1.02%)
META  545.83
-0.20 (-0.04%)
MSFT  481.15
-3.16 (-0.65%)
NVDA  216.85
-0.71 (-0.33%)
ORCL  142.07
-1.74 (-1.21%)
TSLA  345.13
-5.99 (-1.71%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.